Jeffrey S. Ross

61.0k total citations · 7 hit papers
680 papers, 28.7k citations indexed

About

Jeffrey S. Ross is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeffrey S. Ross has authored 680 papers receiving a total of 28.7k indexed citations (citations by other indexed papers that have themselves been cited), including 335 papers in Oncology, 256 papers in Cancer Research and 238 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeffrey S. Ross's work include Cancer Genomics and Diagnostics (202 papers), Lung Cancer Treatments and Mutations (89 papers) and Genetic factors in colorectal cancer (67 papers). Jeffrey S. Ross is often cited by papers focused on Cancer Genomics and Diagnostics (202 papers), Lung Cancer Treatments and Mutations (89 papers) and Genetic factors in colorectal cancer (67 papers). Jeffrey S. Ross collaborates with scholars based in United States, Italy and Spain. Jeffrey S. Ross's co-authors include Jonathan A. Fletcher, Vincent A. Miller, Siraj M. Ali, Lajos Pusztai, W. Fraser Symmans, Gabriel N. Hortobágyi, Philip J. Stephens, Christine E. Sheehan, Alexa B. Schrock and James Stec and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Jeffrey S. Ross

659 papers receiving 28.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

2005 1.4k citations Roman Rouzier, Charles M. Perou et al. Clinical Cancer Research profile →
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

2009 885 citations Jeffrey S. Ross, W. Fraser Symmans et al. The Oncologist profile →
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

1998 799 citations Jeffrey S. Ross et al. profile →
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

2006 553 citations Kenneth R. Hess, K. Anderson et al. profile →
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

2019 441 citations Alexa B. Schrock, Ethan S. Sokol et al. Annals of Oncology profile →
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

2019 429 citations Jason K. Sicklick, Vincent A. Miller et al. profile →
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

2018 374 citations Nikita Pozdeyev, Laurie M. Gay et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Jeffrey S. Ross

Since Specialization

Citations

This map shows the geographic impact of Jeffrey S. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey S. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey S. Ross more than expected).

Fields of papers citing papers by Jeffrey S. Ross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey S. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey S. Ross. The network helps show where Jeffrey S. Ross may publish in the future.

Co-authorship network of co-authors of Jeffrey S. Ross

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey S. Ross. A scholar is included among the top collaborators of Jeffrey S. Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey S. Ross. Jeffrey S. Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study 2024 ·Annals of Oncology ·Tilmann Bochtler, A. Krämer, Chantal Pauli, Gonzalo Durán-Pacheco, Çağatay Arslan, Frédéric Bigot, Nasséra Chalabi, Natalie Cook, Antoîne Italiano, Ferrán Losa, J. Menezes, (unknown), Mustafa Özgüroğlu, (unknown), Jeffrey S. Ross, (unknown), P. Arni, (unknown), Linda Mileshkin	1
2	Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression 2021 ·Journal for ImmunoTherapy of Cancer ·Richard S.P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti Ramkissoon, Jeffrey S. Ross	8
3	CDKN2C -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53 / RB1 –Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion 2020 ·JCO Precision Oncology ·Erik A. Williams, Radwa Sharaf, Brennan Decker, (unknown), (unknown), Meagan Montesion, Ethan S. Sokol, Dean C. Pavlick, (unknown), Kevin Jon Williams, Jeffrey M. Venstrom, Brian M. Alexander, Jeffrey S. Ross, Lee A. Albacker, Douglas I. Lin, Shakti Ramkissoon, Julia A. Elvin	10
4	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation 2019 ·Clinical Cancer Research ·Benjamin P. Brown, Yunkai Zhang, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfang Du, Jarrod A. Smith, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Lyudmila Bazhenova, Alexa B. Schrock, Jens Meiler, Christine M. Lovly	76
5	Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non–Small Cell Lung Cancer Cells 2019 ·Molecular Cancer Research ·Timothy F. Day, Bhaskar Kallakury, Jeffrey S. Ross, (unknown), (unknown), Christine E. Sheehan, Usha N. Kasid	15
6	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers breakdown → 2018 ·Clinical Cancer Research ·Nikita Pozdeyev, Laurie M. Gay, Ethan Sokol, Ryan J. Hartmaier, Kelsi E. Deaver, Stephanie Davis, Jena D. French, Pierre Vanden Borre, Daniel V. LaBarbera, Aik Choon Tan, Rebecca E. Schweppe, Lauren Fishbein, Jeffrey S. Ross, Bryan R. Haugen, Daniel W. Bowles	374
7	Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus 2018 ·Clinical Cancer Research ·Alexa B. Schrock, Dean C. Pavlick, Samuel J. Klempner, Jon Chung, (unknown), Allison W. Welsh, Lauren Young, B Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller	54
8	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis 2017 ·Cancer Research ·Ryan J. Hartmaier, Lee A. Albacker, Juliann Chmielecki, Mark Bailey, Jie He, Michael E. Goldberg, Shakti Ramkissoon, James Suh, Julia A. Elvin, (unknown), Garrett M. Frampton, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, Doron Lipson	85
9	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry 2017 ·Journal of Clinical Pathology ·(unknown), Jeffrey S. Ross, Christine E. Sheehan, Kajsa E. Affolter, Katherine B. Geiersbach, Ann Boguniewicz, Sanaz Ainechi, Mary P. Bronner, David Jones, Hwajeong Lee	18
10	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target 2016 ·Clinical Cancer Research ·Evgeny Yakirevich, Murray B. Resnick, Shamlal Mangray, Michael B. Wheeler, Cynthia L. Jackson, Kara A. Lombardo, Jeeyun Lee, Kyoung‐Mee Kim, Anthony J. Gill, Kai Wang, Kyle Gowen, James Sun, Vincent A. Miller, Philip J. Stephens, Siraj M. Ali, Jeffrey S. Ross, Howard Safran	88
11	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences 2015 ·The Oncologist ·Kai Wang, Adrienne Johnson, Siraj M. Ali, Samuel J. Klempner, Tanios Bekaii‐Saab, Jeffrey Vacirca, Depinder Khaira, Roman Yelensky, Juliann Chmielecki, Julia A. Elvin, Doron Lipson, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross	75
12	Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches 2015 ·Clinical Cancer Research ·Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi	202
13	Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions 2014 ·Cancer Discovery ·Christine M. Lovly, Abha A. Gupta, Doron Lipson, Geoff Otto, Tina Brennan, Catherine T. Chung, Scott C. Borinstein, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Cheryl M. Coffin	303
14	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer 2014 ·Molecular Cancer Therapeutics ·Funda Meric‐Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, José Alejandro Pérez Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pîlar Eroles, Juan Antonio Barrera, Octavio Burgués, Aňa Lluch, Xiaofeng Zheng, Ayşegül Şahin, Philip J. Stephens, Gordon B. Mills, Maureen Cronin, Ana M. González-Angulo	68
15	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes 2014 ·Cancer Discovery ·Juliann Chmielecki, Katherine E. Hutchinson, Garrett M. Frampton, Zachary R. Chalmers, Adrienne Johnson, Chanjuan Shi, Julia A. Elvin, Siraj M. Ali, Jeffrey S. Ross, Olca Baştürk, Sohail Balasubramanian, Doron Lipson, Roman Yelensky, William Pao, Vincent A. Miller, David S. Klimstra, Philip J. Stephens	126
16	BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition 2013 ·Clinical Cancer Research ·Katherine E. Hutchinson, Doron Lipson, Philip J. Stephens, Geoff Otto, Brian D. Lehmann, Pamela L. Lyle, Cindy L. Vnencak‐Jones, Jeffrey S. Ross, Jennifer A. Pietenpol, Jeffrey A. Sosman, Igor Puzanov, Vincent A. Miller, William Pao	124
17	The Proapoptotic Molecule BLID Interacts with Bcl-XL and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival 2010 ·Clinical Cancer Research ·Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca B. Riggins, Anne‐Michelle Noone, Bassem R. Haddad, Françoise Seillier‐Moiseiwitsch, Bhaskar Kallakury, Bruce G. Haffty, Robert Clarke, Usha N. Kasid	15
18	Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy breakdown → 2005 ·Clinical Cancer Research ·Roman Rouzier, Charles M. Perou, W. Fraser Symmans, Nuhad K. Ibrahim, Massimo Cristofanilli, K. Anderson, Kenneth R. Hess, James Stec, Mark Ayers, Peter J. Wagner, Paolo Morandi, (unknown), Rabiul Islam, Jeffrey S. Ross, Gabriel N. Hortobágyi, Lajos Pusztai	1414
19	Genetic alterations in early‐onset invasive breast carcinomas: Correlation of c‐erbB‐2 amplification detected by fluorescence In situ hybridization with p53 accumulation and tumor phenotype 1999 ·International Journal of Cancer ·Maryse Fiche, Hervé Avet‐Loiseau, Marie‐Françoise Heymann, (unknown), (unknown), Madeleine Joubert, Jean‐Marc Classe, F. Dravet, P. Fumoleau, Jeffrey S. Ross, Christine M. Maugard	1
20	Telomerase activity in benign and malignant cytologic fluids 1999 ·Cancer ·(unknown), Thomas P. Brien, Jeffrey S. Ross, Charles V. Lowry, Barbara J. McKenna	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact